Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 16, 2012

Primary Completion Date

November 17, 2023

Study Completion Date

November 17, 2023

Conditions
Congenital Bleeding DisorderHaemophilia B
Interventions
DRUG

nonacog beta pegol

A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.

Trial Locations (20)

100

National Taiwan University Children's Hospital, Taipei

10029

Mount Sinai Medical Center, New York

11220

Maimonides Medical Center, Brooklyn

19104

Children's Hosptl Philadelphia, Philadelphia

20124

Istituto di Medicina Int. A. Bianchi Bonomi Univ. Milano, Milan

30625

Medizinische Hochschule Hannover - Pädiatrische Hämato-, Onko- und Hämostasiologie, Hanover

37232

Vanderbilt Hemostasis Thrombosis Clinic, Nashville

50400

National Blood Centre, Kuala Lumpur

55404

Children's Hospitals And Clinics Of Minnesota, Minneapolis

75235

Children's Medical Center_Dallas, Dallas

M5G 1X8

The Hospital for Sick Children, Toronto

216-8511

St. Marianna University School of Medicine Hospital_Pediatrics, Kanagawa

420-8660

Shizuoka Children's Hospital, Hematology-Oncology, Shizuoka

167-0035

Ogikubo Hospital_Pediatries & Blood, Tokyo

RG24 9NA

Basingstoke & North Hampshire Hospital - Centre for Haemophilia, Haemostasis and Thrombosis, Basingstoke

LE1 5WW

Leicester Royal Infirmary - Haemostasis & Thrombosis Unit, Leicester

Leicester Royal Infirmary, Leicester

SE1 7EH

St Thomas' Hospital - Haemostasis and Thrombosis Centre, London

St Thomas' Hospital, London

OX3 9DU

John Radcliffe Hospital, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY